Main Article Content


Cysticercosis occurs in porcine naturally. A human can be infected by cysticercosis if they swallow Taenia solium's egg inadvertently. These eggs can be found in vegetables or unboiled water. These eggs hatch and later will become larva that becomes cysts in muscle or brain, known as cysticercus cellulose. Neurocysticercosis is an infection of the central nervous system caused by Taenia solium at its larval stage. Indonesia is a developing country with a high incidence rate of neurocysticercosis, with the highest amount of cases found in Bali and Papua. Neurocysticercosis boasts a broad array of clinical symptoms, from silent disease to a severe, debilitating illness that leads to death. The diagnosis of neurocysticercosis itself presents a great challenge, due to the unspecific clinical symptoms, in-pathognomonic radiographic findings and serologic studies with low specificity and sensitivity. The management of neurocysticercosis consists of a combination of antiparasitic agents and supportive therapies, ranging from steroid to surgeries that can be done under certain circumstances.


Antiparasite Cysticercus cellulosae Neurocysticercosis Taenia solium

Article Details

How to Cite
Carrey, M., Suseno, E., Joprang, F. S., Darmawan, O., & Widayanti, R. J. R. (2018). Current trends of diagnosis and management of neurocysticercosis. JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia, 9(3), 187–194.


  1. García HH, Gonzalez A, Evans C, Gilman R. Cysticercosis Working Group in Peru. Taenia solium cysticerosis. Lancet. 2003;362(9383):547–56.
  2. Coral-Almeida M, Gabriël S, Abatih EN, Praet N, Benitez W, Dorny P. Taenia solium human cysticercosis: A systematic review of sero-epidemological data from endemic zones around the world. PLoS Neglected Tropical Diseases. 2015;9(7):1–20.
  3. Zammarchi L, Strohmeyer M, Bartalesi F, Bruno E, Muñoz J, Buonfrate D, et al. Epidemiology and management of cysticercosis and Taenia solium Taeniasis in Europe, systematic review 1990-2011. PLoS One. 2013;8(7): e69537.
  4. Carpio A, Romo ML. State of the art in neurocysticercosis: Imaging and epidemiology. Asian Pacific Journal of Tropical Medicine . 2016;9(8):821–2.
  5. Wanda T, Ito A, Swastika K, Dharmawan N, Sako Y, Okamoto M. Taeniases and cysticercosis in Indonesia: Past and present situations. Parasitology. 2013;140(13):1608–16.
  6. Margono SS, Subahar R, Hamid A, Wandra T, Raka Sudewi SS, Sutisna P, et al. Cysticercosis in Indonesia?: Epidemiological aspects. Southeast Asian Journal of Tropical Medicine Public Health. 2001;32(SUPPL. 2):79–84.
  7. Susanto I, Ismid IS, Sjarifuddin PK, Sungkar S. Buku ajar parasitologi kedokteran. 4ed . Jakarta: Badan Penerbit FKUI; 2015.
  8. Garcia HH, Nash TE, Del Brutto OH. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurology. 2014;13(12):1202–15.
  9. Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, et al. Clinical manifestations associated with neurocysticercosis: A systematic review. PLoS Neglected Tropical Diseases. 2011;5(5):e1152.
  10. Sotelo J. Clinical manifestations, diagnosis, and treatment of neurocysticercosis. Current Neurology and Neuroscience Reports. 2011;11(6):529–35.
  11. Singhi P, Suthar R. Neurocysticercosis. Indian Journal of Pediatrics. 2015;82(2):166–71.
  12. Del Brutto OH. Diagnostic criteria for neurocysticercosis, revisited. Pathogens and Global Health [Internet]. 2012;106(5):299–304.
  13. Sudewi RAA, Sugianto P, Ritarwan K. Infeksi pada sistem saraf. Surabaya: Airlangga University Press; 2011.
  14. Proaño-Narvaez J V., Meza-Lucas A, Mata-Ruiz O, García-Jerónimo RC, Correa D. Laboratory diagnosis of human neurocysticercosis: Double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. Journal of Clinical Microbiology. 2002;40(6):2115–8.
  15. Dhesi B, Karia SJ, Adab N, Nair S. Imaging in neurocysticercosis. Pract Neurol. 2015;15:135–7.
  16. Zhao J-L, Lerner A, Shu Z, Gao X-J, Zee C-S. Imaging spectrum of neurocysticercosis. Radiology of Infectious Diseases. 2015;1(2):94–102.
  17. Jung-Cook H. Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis. Expert Review of Clinical Pharmacology. 2012;5(1):21–30.
  18. Cárdenas G, Carrillo-Mezo R, Jung H, Sciutto E, Hernandez JLS, Fleury A. Subarachnoidal neurocysticercosis non-responsive to cysticidal drugs: A case series. BMC Neurol. 2010;10:16.
  19. Gripper LB, Welburn SC. Neurocysticercosis infection and disease–A review. Acta Tropica . 2017;166:218–24.
  20. Chai JY. Praziquantel Treatment in Trematode and Cestode Infections: An Update. Infection and Chemotherapy. 2013;45(1):32–43.
  21. Brunton LL, Chabner BA KB. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
  22. Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: A meta-analysis of comparative trials. PLoS Neglected Tropical Diseases. 2008;2(3):e194.
  23. Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial.Lancet Infectious Diseases. 2014;14(8):687–95.
  24. Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H, et al. Effects of albendazole treatment on neurocysticercosis: A randomised controlled trial. Journal of Neurology, Neurosurgery, and Psychiatr. 2008;79(9):1050–5.
  25. Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL. Evidence-based guideline: Treatment of parenchymal neurocysticercosis: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2013;80(15):1424–9.
  26. Nash TE, Mahanty S, Garcia HH. Corticosteroid use in neurocysticercosis. Expert Review of Neurotherapeutics. 2011;11(8):1175–83.